FCSC News and Press, Fibrocell Science Inc. From 04/15/19

Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% .  SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...

Fibrocell Science (NASDAQ: FCSC ) +56%  on Castle Creek collaboration . More news on: Fibrocell Science, Inc., Bio-Path Holdings, Inc., Electronics for Imaging, Inc., Stocks on the move, Read more ...

Nano cap Fibrocell Science (NASDAQ: FCSC ) is up  51%  premarket on robust volume in response to its collaboration with Castle Creek Pharmaceuticals to develop and commercialize gene therapy candidate FCX-007 for recessive dystrophic epidermolysis bullosa, a rare inherited disord...

- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease Priority Review Voucher - - Phase 3 clinical trial (DEFI-RDEB) in...

- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts - EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and conn...

The Company Krystal Biotech Inc. ( KRYS ) is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017 . It develops novel, "off-the-shelf", topical gene therapies for serious genetic skin diseases. Based on the strength ...

Fibrocell Science, Inc. (FCSC) Q4 2018 Earnings Conference Call March 27, 2019 08:30 AM ET Company Participants Karen Casey - IR John Maslowski - President and CEO Alfred Lane - Chief Medical Advisor Sean Buckley - VP, Business Administration Conference Call Participants ...

The following slide deck was published by Fibrocell Science, Inc. in conjunction with their 2018 Q4 earnings Read more ...

Moleculin Biotech (NASDAQ: MBRX )  -25%  on announcing equity offering. More news on: Moleculin Biotech, Inc., DropCar, Inc., Fibrocell Science, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Fibrocell Science (NASDAQ: FCSC ) slips  18%  premarket on light volume on the heels of updated results from a Phase 1/2 clinical trial evaluating gene therapy FCX-007 in adults with recessive dystrophic epidermolysis bullosa (RDEB), an inherited disorder c...